2001
Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy?
Zheng F, Cai W, Mitsuhashi T, Vlassara H, Bucala R. Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy? Molecular Medicine 2001, 7: 737-747. PMID: 11788787, PMCID: PMC1950004, DOI: 10.1007/bf03401963.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsSerum advanced glycation endproductsDb/db miceNon-obese diabeticSerum AGEsMesangial cellsDb miceAGE-BSAGlycation endproductsIGF-I productionDiabetic renal damageSprague-Dawley ratsAGE clearanceSuppress macrophagesNOD miceDiabetic nephropathyRenal damageRenal excretionNormal ratsMMP-9Type IV collagenHost defense proteinsExcretionMRNA levelsMiceImmunological Detection of a Novel Advanced Glycation End-Product
Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z. Immunological Detection of a Novel Advanced Glycation End-Product. Molecular Medicine 2001, 7: 783-791. PMID: 11788793, PMCID: PMC1950006, DOI: 10.1007/bf03401969.Peer-Reviewed Original Research
2000
Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons
Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z. Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons. Journal Of Neuropathology & Experimental Neurology 2000, 59: 1094-1105. PMID: 11138929, DOI: 10.1093/jnen/59.12.1094.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesAntibody SpecificityApoptosisCell SurvivalCells, CulturedCerebral CortexGlycation End Products, AdvancedMolecular WeightNeuronsNeurotoxinsRatsConceptsCortical neuronsAge 2Alzheimer's diseaseEnd-stage renal diseaseNeuronal cellsAdvanced glycation end productsDM HD patientsGreater cytopathic effectsSpecific antibodiesAnti-AGE antibodyCultured cortical neuronsDose-dependent increaseGlycation end productsBlood of individualsCultured neuronal cellsDiabetes mellitusDiabetic patientsRenal diseaseNeurodegenerative processesNormal controlsAdvanced glycationCytopathic effectEpitope 1Cytotoxic effectsMTT assayImmunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCattleChromatography, AffinityCross ReactionsDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycation End Products, AdvancedGlyceraldehydeGlyoxalHumansImmunoblottingKidney Failure, ChronicLysineMaillard ReactionOxidation-ReductionPyruvaldehydeRabbitsRenal DialysisConceptsAGE antibodyCML-AGEDiabetic patientsAGE-bovine serum albuminShort Chain SugarsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsAutoxidation of sugarsImmunization of rabbitsCML-BSADiabetic serumSerum albuminAdvanced glycationAGE contentSugar autoxidationRabbit serum albuminAGE modificationAntibodiesImmunological evidenceApparent molecular weightPatientsAge 3AgeImmunoblot analysis
1999
Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †
Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsLow-density lipoproteinAGE-modified formCertain diabetic complicationsClasses of antibodiesBeta-amyloid peptideDiabetic complicationsPathological sequelaePrognostic informationAGE formationAGE adductsImmunoreactive fractionEnd productsInhibition of formationVivo ageAgeAntibodiesLines of evidenceVivoCross-linking adductsGlucoseTissueComplicationsInhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol
Al-Abed Y, Mitsuhashi T, Li H, Lawson J, FitzGerald G, Founds H, Donnelly T, Cerami A, Ulrich P, Bucala R. Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardioprotective effect of ethanol. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 2385-2390. PMID: 10051651, PMCID: PMC26793, DOI: 10.1073/pnas.96.5.2385.Peer-Reviewed Original Research
1998
Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers
Nicholl I, Stitt A, Moore J, Ritchie A, Archer D, Bucala R. Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers. Molecular Medicine 1998, 4: 594-601. PMID: 9848076, PMCID: PMC2230315, DOI: 10.1007/bf03401759.Peer-Reviewed Original ResearchMeSH KeywordsAgedCataractCataract ExtractionCoronary VesselsFemaleGlycation End Products, AdvancedHumansLens, CrystallineMaleMicroscopy, ImmunoelectronSmokingConceptsNondiabetic smokersTissues of smokersCoronary arteryGlycation endproductsSingle greatest preventable causeGreatest preventable causeEnd-organ complicationsAnti-AGE antibodyConsequence of diabetesAdvanced glycation endproductsRenal insufficiencyCigarette smokersPreventable causeSmokersCigarette smokeHigh levelsCausal associationNonsmokersDiabetesMainstream cigarette smokeBlood vesselsAgeExtracellular matrix proteinsArteryLens fiber cellsIdentification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product
Al-Abed Y, Schleicher E, Voelter W, Liebich H, Papoulis A, Bucala R. Identification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product. Bioorganic & Medicinal Chemistry Letters 1998, 8: 2109-2110. PMID: 9873495, DOI: 10.1016/s0960-894x(98)00398-9.Peer-Reviewed Original ResearchGlucoseGlycation End Products, AdvancedGuanineIndicators and ReagentsMolecular StructureOxidation-ReductionEpitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products
Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 7643-7647. PMID: 9636203, PMCID: PMC22709, DOI: 10.1073/pnas.95.13.7643.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalApolipoproteins BBinding SitesBinding, CompetitiveCell LineEpitopesGlycation End Products, AdvancedHumansRadioimmunoassayReceptors, LDLStructure-Activity RelationshipConceptsAdvanced glycation end productsLow-density lipoproteinGlycation end productsLDL receptorAGE modificationAbnormal lipoprotein profilesGlycation of LDLInability of LDLPrevious immunochemical studiesRenal failureLipoprotein profileTime-dependent decreaseCardiovascular diseaseApolipoprotein BAdvanced glycationDensity lipoproteinReceptor-binding siteEnd productsImmunochemical studiesEpitopesGlycationCellular uptakeMultiple sitesPatientsDiabetesAdvanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral Sclerosis
Chou S, Wang H, Taniguchi A, Bucala R. Advanced Glycation Endproducts in Neurofilament Conglomeration of Motoneurons in Familial and Sporadic Amyotrophic Lateral Sclerosis. Molecular Medicine 1998, 4: 324-332. PMID: 9642682, PMCID: PMC2230387, DOI: 10.1007/bf03401739.Peer-Reviewed Original ResearchMeSH KeywordsAmyotrophic Lateral SclerosisBrain ChemistryGlycation End Products, AdvancedHumansImmunohistochemistryMotor NeuronsNeurofilament ProteinsSpinal CordConceptsAmyotrophic lateral sclerosisSporadic amyotrophic lateral sclerosisNeurofilament proteinNeuronal inclusionsLateral sclerosisAGE formationNitric oxide-mediated responsesAnti-AGE antibodyAdvanced glycation endproductsMethodsParaffin sectionsMotor neuronsConclusionsThese dataAdvanced glycationGlycation endproductsNeuronal toxicityNitric oxideSpecific antibodiesProtein nitrationConcomitant inductionSclerosisSuperoxide dismutasePatientsAntibodiesPotent oxidantFree radicalsRole of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes
Sherry B, Zybarth G, Alfano M, Dubrovsky L, Mitchell R, Rich D, Ulrich P, Bucala R, Cerami A, Bukrinsky M. Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 1758-1763. PMID: 9465090, PMCID: PMC19180, DOI: 10.1073/pnas.95.4.1758.Peer-Reviewed Original ResearchConceptsHIV-1 infectionT lymphocytesPrimary peripheral blood mononuclear cellsPeripheral blood mononuclear cellsBlood mononuclear cellsHIV-1 virionsCyclophilin ACytokine-like mannerEarly eventsMononuclear cellsHIV therapyT cellsHIV-1Viral infectionViral infectivityInfectionCsA analoguesCellular receptorsLymphocytesCypAReceptorsCellsCell surfaceCD4Peptidyl-prolyl cis-trans isomerase activityAminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit
Panagiotopoulos S, O'Brien R, Bucala R, Cooper M, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998, 136: 125-131. PMID: 9544739, DOI: 10.1016/s0021-9150(97)00192-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArteriosclerosisCholesterolCholesterol, DietaryEnzyme InhibitorsGlycation End Products, AdvancedGuanidinesLipidsMalePilot ProjectsRabbitsThiobarbituric Acid Reactive SubstancesConceptsAdvanced glycosylation endproductsAortic archAbdominal aortaAdvanced glycationPlaque formationVasculopathy of diabetesAnti-atherogenic effectsHigh-cholesterol dietCholesterol-fed rabbitsDevelopment of atherosclerosisDegree of atheromaCholesterol dietAortaAtheromaRabbitsThoracicAminoguanidineDosesGlycationTreatmentArchAge levelsNon-enzymatic interactionVasculopathySudan IV
1997
Tobacco smoke is a source of toxic reactive glycation products
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 13915-13920. PMID: 9391127, PMCID: PMC28407, DOI: 10.1073/pnas.94.25.13915.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsTobacco smokeGlycation productsAGE formationSerum AGE levelsIncidence of atherosclerosisPlasma of patientsGlycation end productsRenal insufficiencyCerebrovascular diseaseCigarette smokersHuman smokersHigh prevalenceHigh riskSmokersNonsmokersGlycotoxinsPatientsSpecific fluorescenceSerum proteinsDiseaseCuring of tobaccoAqueous extractSmokeTobaccoReduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia
Fishbane S, Bucala R, Pereira B, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney International 1997, 52: 1645-1650. PMID: 9407512, DOI: 10.1038/ki.1997.497.Peer-Reviewed Original ResearchMeSH KeywordsApolipoproteins BFemaleGlycation End Products, AdvancedHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesRenal DialysisUremiaConceptsAdvanced glycation endoproductsLow density lipoprotein clearanceLong-term hemodialysis therapyRenal replacement treatmentEffect of hemodialysisAGE removalDiabetic ESRDSerum apoBESRD patientsRenal insufficiencyClinical outcomesLipoprotein clearancePlasma apoBHemodialysis therapyReplacement treatmentApoliprotein BPatientsGroup subjectsHemodialysis filtersReactive substancesApoBPlasma apolipoproteinsAGE clearanceBaselineClearanceMolecular Characterization of a Mouse Genomic Element Mobilized by Advanced Glycation Endproduct Modified-DNA (AGE-DNA)
Pushkarsky T, Rourke L, Spiegel L, Seldin M, Bucala R. Molecular Characterization of a Mouse Genomic Element Mobilized by Advanced Glycation Endproduct Modified-DNA (AGE-DNA). Molecular Medicine 1997, 3: 740-749. PMID: 9407550, PMCID: PMC2230240, DOI: 10.1007/bf03401712.Peer-Reviewed Original ResearchElevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs
Stitt A, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li Y, Bucala R, Vlassara H. Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs. Molecular Medicine 1997, 3: 617-627. PMID: 9323713, PMCID: PMC2230092, DOI: 10.1007/bf03401819.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAgingApolipoproteins BArteriosclerosisCarotid ArteriesCollagenEndothelium, VascularEnzyme-Linked Immunosorbent AssayFemaleGlycation End Products, AdvancedHumansImmunohistochemistryMacrophagesMaleMicroscopy, FluorescenceMiddle AgedReceptor for Advanced Glycation End ProductsReceptors, ImmunologicRegression AnalysisConceptsSmooth muscle cellsAGE-specific receptorsMononuclear cellsAtherosclerotic vascular diseaseOcclusive atherosclerotic diseaseDevelopment of hyperlipidemiaLipid-laden macrophagesYoung healthy personsEarly-stage lesionsCardiac bypass patientsAGE-R1Nondiabetic patientsAsymptomatic patientsAsymptomatic personsBypass patientsNormolipidemic patientsAtherosclerotic diseaseDistribution of ageVascular diseaseInflammatory responseLate-stage plaquesAtheromatous lesionsEarly lesionsFatty streaksNondiabetic etiologyOrally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
Koschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6474-6479. PMID: 9177242, PMCID: PMC21074, DOI: 10.1073/pnas.94.12.6474.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsDietary advanced glycation endproductsEndogenous advanced glycation endproductsDiabetes mellitusKidney diseaseRenal excretionRenal vascular injuryDiabetic nephropathy patientsSerum AGE levelsDegree of albuminuriaNondiabetic kidney diseaseEnvironmental risk factorsAGE immunoreactivityRenal complicationsCreatinine clearanceDiabetic nephropathyNephropathy patientsRenal failureDiabetic patientsRisk factorsFood intakeHealthy subjectsGlycation endproductsDietary restrictionCL dietAtherogenesis and Advanced Glycation: Promotion, Progression, and Preventiona
STITT A, BUCALA R, VLASSARA H. Atherogenesis and Advanced Glycation: Promotion, Progression, and Preventiona. Annals Of The New York Academy Of Sciences 1997, 811: 115-129. PMID: 9186590, DOI: 10.1111/j.1749-6632.1997.tb51994.x.Peer-Reviewed Original Research
1996
Glycation and microglial reaction in lesions of Alzheimer's disease
Dickson D, Sinicropi S, Yen S, Ko L, Mattiace L, Bucala R, Vlassara H. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiology Of Aging 1996, 17: 733-743. PMID: 8892346, DOI: 10.1016/0197-4580(96)00116-9.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAGE immunoreactivityNeurofibrillary tanglesExtracellular neurofibrillary tanglesAmyloid depositsMicroglial reactionActivation of microgliaIntracellular neurofibrillary tanglesAlzheimer's disease brainPattern of immunoreactivityGlycation end productsTriple immunostainingDisease brainSenile plaquesDiffuse amyloidAlzheimer's diseaseImmunoreactivityCryostat sectionsDouble labelingAntibodiesMicrogliaLesionsPolyclonal antibodiesDiseaseGlycationEffects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
Soulis T, Cooper M, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney International 1996, 50: 627-634. PMID: 8840295, DOI: 10.1038/ki.1996.358.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDiabetes Mellitus, ExperimentalDiabetic NephropathiesGlycation End Products, AdvancedGuanidinesMaleRatsRats, Sprague-DawleyTime FactorsConceptsRenal advanced glycation end productsAdvanced glycation end productsExperimental diabetic nephropathyDiabetic nephropathyEffect of aminoguanidineDiabetic ratsAminoguanidine treatmentMesangial expansionStudy periodAccumulation of AGEsUrinary albumin excretionTiming of therapyDevelopment of albuminuriaWeeks of treatmentDuration of treatmentGlycation end productsTiming of treatmentPresence of aminoguanidineAminoguanidine administrationAminoguanidine therapyAlbumin excretionRenoprotective effectsTissue fluorescenceExperimental diabetesLate administration